期刊
CELL HOST & MICROBE
卷 22, 期 2, 页码 207-216出版社
CELL PRESS
DOI: 10.1016/j.chom.2017.07.010
关键词
-
资金
- National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH)
- Bill and Melinda Gates Foundation [OPP1124068]
- Bill and Melinda Gates Foundation [OPP1124068] Funding Source: Bill and Melinda Gates Foundation
The neutralizing antibodies targeting the HIV-1 envelope protein have been a major focus for HIV therapy. Early studies with anti-HIV-1 neutralizing monoclonal antibodies (mAbs) administered to infected individuals showed some promise, as they resulted in transient reductions in plasma viremia in some recipients. However, resistant viral variants rapidly emerged. A major development during the past 6 to 7 years has been the isolation and characterization of highly potent and broadly neutralizing mAbs (bNAbs) from infected individuals known as elite neutralizers. These next-generation bNAbs have been tested in animal model systems and shown to effectively control virus replication, particularly following combination immunotherapy. The success of these preclinical animal studies has led to human clinical trials using an individual bNAb for therapy. This review examines recent findings from animal models and human clinical trials and discusses the future use of bNAbs for HIV-1 treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据